Abstract:AIM:To study the transfection and anti-hepatitis B virus (HBV) effect of the co-modified hepatocytes-targeting cationic liposomes encapsulating anti-HBV antisense oligonucleotides (asON) , and to investigate the transfection mechanisms of the liposomes.METHODS:Dipalmitoylphosphatidylcholine (DPPC) and 3beta-[N-(N',N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) were used as the lipids, beta-sitosterol-beta-D-glucoside (sito-G) and Brij 35 were used to modify the liposomes. Flow cytometry (FCM), fluorescence microscopy and enzyme-linked immunosorbent assay (ELISA) were utilized to evaluate the transfection improvement of the asON encapsulated in the liposomes in primary rat hepatocytes and the antigens inhibition activity in HepG 2.2.15 cells. The transfection mechanisms were evaluated based on the influence of wortmannin, nigericin, and asialofetuin on the antigens inhibition in HepG 2.2.15 cells by ELISA.RESULTS:The co-modification with sito-G and Brij 35 significantly improved the transfection of the liposomes in primary rat hepatocytes and antigens inhibition effect in HepG 2.2.15 cells. Both transfection efficiency and antigens inhibition effect showed to be concentration-dependent with the asON-encapsulating liposomes. In fluorescence microscopy, the transfected cells showed strong fluorescence in primary rat hepatocytes, especially in the nuclei. Wortmannin, nigericin and asialofetuin decreased the antigens inhibition of the asON-encapsulating liposomes to different levels. Cationic liposomes modification with sito-G and Brij 35 could improve the transfection and antigens inhibition effect of the asON. The transfection mechanisms of the co-modified liposomes included endocytosis and membrane fusion. The ligand sito-G was confirmed to be able to enhance asialoglycoprotein receptor (ASGPR)-mediated endocytosis.CONCLUSION:Co-modified hepatocytes-targeting cationic liposomes would be a specific and effective carrier to transfer asON into hepatocytes.

[Preparation of Nosiheptide Liposomes and Its Inhibitory Effect on Hepatitics B Virus in Vitro].

Biologic Activity Estimation of Anti-hepatitis B Immune RNA Wrapped in Liposome in Mice

Recombinant High-Density Lipoprotein Complex As a Targeting System of Nosiheptide to Liver Cells.

Study on Preparation of Acyclovir Liposomes and Its Role in Inhibiting Hepatitics B in Vitro

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

INHIBITION OF HEPATITIS B VIRUS BY COMBINED Sirnas IN VITRO

[Cationic liposomes enhance the inhibitory effects of antisense oligodeoxynucleotide on hepatitis B virus].

[Transfection and Anti-Hbv Effect Mediated by the Hepatocytes-Targeting Cationic Liposomes Co-Modified with Beta-Sitosterol-beta-d-glucoside and Brij 35].

Design, Synthesis and Bioactive Evaluation of Oxime Derivatives of Dehydrocholic Acid as Anti-Hepatitis B Virus Agents

Characteristics and Biodistribution of Soybean Sterylglucoside and Polyethylene Glycol-Modified Cationic Liposomes and Their Complexes with Antisense Oligodeoxynucleotide

Repurposing of Antazoline Hydrochloride as an Inhibitor of Hepatitis B Virus DNA Secretion

Inhibition of Hepatitis B Virus Gene Expression by Single and Dual Small Interfering RNA Treatment

Increase of Hepatitis B Surface Antigen Loss Rate in Hepatitis B E Antigen Positive Chronic Hepatitis B Patients Treated with Nucleos (t) Ide Analogs and Pegylated Interferon Alfa-2A Sequential Therapy

Antiviral effect of peptoids on hepatitis B virus infection in cell culture

[Inhibition of HBsAg and HBeAg Secretion by RNA Interference of the Polymerase Gene Sequence of Hepatitis B Virus: an Experimental Study].

Cost-effective Method of Sirna Preparation and Its Application to Inhibit Hepatitis B Virus Replication in HepG2 Cells.

Inhibition of Hepatitis B Virus Surface Antigen Expression by Small Hairpin RNAin Vitro

Efficient Inhibition of Hepatitis B Virus Infection by a Pres1-Binding Peptide

Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B

Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect.